|
Indian CDMOs move from manufacturing service providers into strategic innovation partners: Aditya Sharma
|
|
Nandita Vijayasimha, Bengaluru
November 17 , 2026
|
|
|
Indian pharmaceutical sector has evolved from being primarily a cost-efficient manufacturing destination to becoming an increasingly important partner in global drug discovery, development and innovation. Contract development and manufacturing organisations (CDMOs) are contributing to this shift by enabling companies to develop products more efficiently and economically, said Aditya Sharma, managing director, Fertin Pharma India.
As businesses increasingly outsource product development and manufacturing, demand for trustworthy CDMO partners is growing. India’s expanding network of pharmaceutical manufacturers and CDMOs covers traditional formulations, biologics and advanced drug delivery systems, opening a world of possibilities for global companies, he added.
Supported by robust regulatory frameworks, proven manufacturing capabilities and competitive cost structures, Indian CDMOs are increasingly evolving from manufacturing service providers into strategic innovation partners, Sharma told Pharmabiz.
Companies are now seeking partners that can help with formulation development, innovation and concept-to-product translation. For smaller businesses, collaboration with CDMOs enables product development and market entry without significant investment in their own facilities, he noted.
Advanced and differentiated drug delivery systems represent one of the most promising growth opportunities for Indian CDMOs. As patient-centric healthcare gains importance globally, pharmaceutical and consumer healthcare companies are increasingly exploring convenient, easy-to-use formats that can improve compliance and overall user experience. These might include oral dosage forms, patches, injections and other specialised options, depending on the therapy, target consumer base and other requirements, said Sharma.
The nutraceutical and wellness sectors are emerging as significant growth drivers for CDMOs globally. Growing consumer focus on preventive healthcare, self-care and wellness is driving demand for innovative delivery formats beyond traditional tablets and capsules. Chewing gum and mint formats, among others, could offer alternative ways for consumers to integrate supplements into their lifestyles. Consumer research would be needed to assess demand, understand preferences and guide the development of such formats, he noted.
Maintaining competitiveness would depend on continued investment in manufacturing infrastructure, automation, technology and R&D skills. Plants are increasingly expected to meet regulatory and cost requirements while ensuring reproducibility and quality assurance. Technology adoption should take profitability into account, especially in price-sensitive markets. Collaboration between pharmaceutical firms, CDMOs and academic and research institutions would further hasten innovation by translating scientific findings into technological applications, formulations and products. AI and digital technologies are expected to play an increasingly important role across formulation development, process optimisation, quality management and manufacturing efficiency, helping accelerate time-to-market while maintaining high quality standards, he said.
We see India as a strategically important market and a key contributor to our global growth ambitions. At Fertin Pharma, supported by an R&D team of 15 scientists, our manufacturing facility in Goa and a network of nutraceutical production partners, we serve customers across India and international markets. Looking ahead, we will continue to strengthen our leadership in nicotine replacement therapy while expanding our nutraceutical portfolio and advancing innovative oral delivery formats such as medicated chewing gums, functional gums and mints. We believe these patient-friendly and consumer-centric formats will play an increasingly important role in the future of healthcare and wellness, said Sharma.
|
|

|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|